These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus. Moore KB; Saudek CD Am J Ther; 2008; 15(5):484-91. PubMed ID: 18806525 [TBL] [Abstract][Full Text] [Related]
5. Cardiovascular biology of the incretin system. Ussher JR; Drucker DJ Endocr Rev; 2012 Apr; 33(2):187-215. PubMed ID: 22323472 [TBL] [Abstract][Full Text] [Related]
6. Incretins: their physiology and application in the treatment of diabetes mellitus. Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141 [TBL] [Abstract][Full Text] [Related]
7. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application]. Winkler G Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951 [TBL] [Abstract][Full Text] [Related]
8. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. Jellinger PS Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084 [TBL] [Abstract][Full Text] [Related]
9. Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes. González N; Moreno-Villegas Z; González-Bris A; Egido J; Lorenzo Ó Cardiovasc Diabetol; 2017 Apr; 16(1):44. PubMed ID: 28376896 [TBL] [Abstract][Full Text] [Related]
11. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Freeman JS Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298 [TBL] [Abstract][Full Text] [Related]
12. Incretin-based therapy of type 2 diabetes mellitus. Knop FK; Vilsbøll T; Holst JJ Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects of incretins in diabetes. Advani A; Bugyei-Twum A; Connelly KA Can J Diabetes; 2013 Oct; 37(5):309-14. PubMed ID: 24500557 [TBL] [Abstract][Full Text] [Related]
14. [Modulation of the incretin effect in the treatment of diabetes]. Vidal J Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Effects of Incretin-Based Therapies. White WB; Baker WL Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797 [TBL] [Abstract][Full Text] [Related]
18. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. Triplitt C; Wright A; Chiquette E Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716 [TBL] [Abstract][Full Text] [Related]
19. Treating type 2 diabetes: incretin mimetics and enhancers. Janosz KE; Zalesin KC; Miller WM; McCullough PA Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):387-95. PubMed ID: 19808944 [TBL] [Abstract][Full Text] [Related]
20. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Verspohl EJ Pharmacol Ther; 2009 Oct; 124(1):113-38. PubMed ID: 19545590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]